These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 6574695

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C, Hunter C, Jankovic J.
    Mov Disord; 2007 Jan 15; 22(2):193-7. PubMed ID: 17133512
    [Abstract] [Full Text] [Related]

  • 3. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ, Ondo WG, Dashtipour K, Swope DM.
    Clin Ther; 2012 Jul 15; 34(7):1487-504. PubMed ID: 22749259
    [Abstract] [Full Text] [Related]

  • 4. Analysis of CYP2D6 genotype and response to tetrabenazine.
    Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J.
    Mov Disord; 2013 Feb 15; 28(2):210-5. PubMed ID: 23280482
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Therapeutic use of tetrabenazine].
    López Del Val LJ, López-García E, Martínez-Martínez L, Santos-Lasaosa S.
    Rev Neurol; 2013 Feb 15; 48(10):523-33. PubMed ID: 19434587
    [Abstract] [Full Text] [Related]

  • 9. [Hyperkinetic syndromes. Therapeutic trials].
    Severini P, Pompili A, Pierini G.
    Riv Neurol; 1978 Feb 15; 48(2):242-8. PubMed ID: 276041
    [Abstract] [Full Text] [Related]

  • 10. Drug treatment of diseases characterized by abnormal movements.
    Marsden CD.
    Proc R Soc Med; 1973 Sep 15; 66(9):871-3. PubMed ID: 4281483
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tetrabenazine and movement disorders.
    Asher SW, Aminoff MJ.
    Neurology; 1981 Aug 15; 31(8):1051-4. PubMed ID: 6455607
    [Abstract] [Full Text] [Related]

  • 13. Tetrabenazine treatment in movement disorders.
    Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S.
    Clin Neuropharmacol; 2004 Aug 15; 27(5):230-3. PubMed ID: 15602104
    [Abstract] [Full Text] [Related]

  • 14. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR.
    Am J Geriatr Pharmacother; 2010 Aug 15; 8(4):331-73. PubMed ID: 20869622
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Drug treatment of hyperkinetic movement disorders.
    Fahn S.
    Semin Neurol; 1987 Jun 15; 7(2):192-208. PubMed ID: 3332454
    [No Abstract] [Full Text] [Related]

  • 19. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
    Jankovic J, Orman J.
    Neurology; 1988 Mar 15; 38(3):391-4. PubMed ID: 3279337
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of tetrabenazine in hyperkinetic movement disorders.
    Jankovic J, Beach J.
    Neurology; 1997 Feb 15; 48(2):358-62. PubMed ID: 9040721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.